Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7051536 | 0.89 | KCNJ1 (0.54) | KCNJ1KCNH2TAAR1SIGMAR1ALDH1A1 | |
| SCHEMBL6029221 | 0.84 | FFAR1 (0.43) | KCNJ1KCNH2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL17541809 | 0.83 | TSHR (0.46) | KCNJ1KCNH2SIGMAR1ALDH1A1 | |
| SCHEMBL29225788 | 0.81 | TSHR (0.40) | KCNJ1KCNH2ALDH1A1NPC1RAB9A | |
| SCHEMBL9515359 | 0.81 | CYP19A1 (0.46) | KCNJ1KCNH2ALDH1A1NPC1MAPT | |
| SCHEMBL9323722 | 0.80 | IDO1 (0.48) | KCNJ1KCNH2TAAR1ALDH1A1NPC1 | |
| SCHEMBL11739468 | 0.79 | MMP12 (0.41) | KCNJ1KCNH2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8766421 | 0.79 | TAAR1 (0.57) | TAAR1SIGMAR1ALDH1A1MAPTAOC3 | |
| SCHEMBL509784 | 0.79 | KCNH2 (0.49) | KCNH2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL509897 | 0.78 | FFAR1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3305763-B1 | DEUTERATED OR ISOTOPICALLY LABELED UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FPRL-1 AGONISTS | KYORIN SEIYAKU KK (JP) | 2019-07-24 | — | — | EP | disclosed |
| EP-3305763-A1 | DEUTERATED OR ISOTOPICALLY LABELED UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FPRL-1 AGONISTS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2018-04-11 | — | — | EP | disclosed |
| EP-3075726-B1 | UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FORMYL PEPTIDE RECEPTOR LIKE 1 (FPRL-1) AGONISTS | KYORIN SEIYAKU KK (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-8105567-B2 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | BRACCO IMAGING SPA (IT) | 2012-01-31 | — | — | US | disclosed |
| US-8105567-B2 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | BRACCO IMAGING SPA (IT) | 2012-01-31 | — | — | US | disclosed |
| US-8105567-B2 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | BRACCO IMAGING SPA (IT) | 2012-01-31 | — | — | US | disclosed |
| US-20110082280-A1 | Methods Of Coupling Multidentate AZA Ligands To Targeting Molecules | BRACCO IMAGING S.P.A. (IT) | 2011-04-07 | — | — | US | disclosed |
| US-20110082280-A1 | Methods Of Coupling Multidentate AZA Ligands To Targeting Molecules | BRACCO IMAGING S.P.A. (IT) | 2011-04-07 | — | — | US | disclosed |
| US-7893223-B2 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | BRACCO IMAGING S.P.A. (IT) | 2011-02-22 | — | — | US | disclosed |
| US-7893223-B2 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | BRACCO IMAGING S.P.A. (IT) | 2011-02-22 | — | — | US | disclosed |
| WO-2006136564-A9 | MULTIDENTATE AZA LIGANDS ABLE TO COMPLEX METAL IONS AND THE USE THEREOF IN DIAGNOSTICS AND THERAPY | BRACCO IMAGING SPA (IT) | 2008-02-07 | — | — | WO | disclosed |
| WO-2006136564-A1 | MULTIDENTATE AZA LIGANDS ABLE TO COMPLEX METAL IONS AND THE USE THEREOF IN DIAGNOSTICS AND THERAPY | BRACCO IMAGING S.P.A. (IT) | 2006-12-28 | — | — | WO | disclosed |
| US-20060034773-A1 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | BRACCO IMAGING SPA (IT) | 2006-02-16 | — | — | US | disclosed |
| EP-0821674-B1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | SEARLE & CO (US) | 2003-08-06 | — | — | EP | disclosed |
| US-6043261-A | TREATMENT OF INFLAMMATORY CONDITIONS AFFECTING THE JOINTS, FOR EXAMPLE ARTHRITIS, INFLAMMATORY BOWEL DISEASE, CARDIOVASCULAR ISCHEMIA, DIABETES, HYPERALGESIA, CEREBRAL ISCHEMIA, THROMBOTIC STROKE, GLOBAL ISCHEMIA, NERVOUS SYSTEM DISORDERS | G. D. SEARLE & CO. (US) | 2000-03-28 | — | — | US | disclosed |
| US-6011028-A | Cyclic amidino agents useful as nitric oxide synthase inhibitors | G.D. SEARLE & CO. (US) | 2000-01-04 | — | — | US | disclosed |
| US-5883251-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 1999-03-16 | — | — | US | disclosed |
| EP-0821674-A1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033175-A1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-10-24 | — | — | WO | disclosed |
| US-3935219-A | Antimicrobial dihalonitromethylisoxazoles | PURDUE RESEARCH LABORATORY (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060034773-A1 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | SSTR3, MB, CA13 | KCNJ1 4841/4885KCNH2 2020/4885TAAR1 307/4885 |
| US-20110082280-A1 | Methods Of Coupling Multidentate AZA Ligands To Targeting Molecules | CD99, CD209, PRMT9 | KCNJ1 4862/4885KCNH2 3984/4885TAAR1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.